an increased number of C. difficile erm(B)-negative isolates resistant to MLSB has been described, including strains characterized as PCR ribotype 027 (1, 19) .
Historically, fluoroquinolones were considered a low risk in C. difficile diseases, but recent evidence strongly suggests an association between their use and CDI (6, 24, 26) . Resistance to fluoroquinolones has been described not only in the epidemic strain 027 but also in other important PCR ribotypes, and it is increasing, since recent data have shown that resistant strains represent 37.5% of C. difficile clinical isolates in Europe (2) . Two main mechanisms of fluoroquinolone resistance have been described: alterations in the targets of antibiotics, DNA gyrase and topoisomerase IV, and decreased accumulation inside bacteria (13, 29) . In C. difficile, as in many other bacterial species, resistance is determined by amino acid substitutions in the quinolone resistance-determining region (QRDR) of the target enzymes (27) . Since this bacterium does not have genes for topoisomerase IV, these alterations are located in the QRDR of either GyrA or GyrB, the DNA gyrase subunits (11, 34) . Recent studies indicated that the replacement of Thr82 with Ile in GyrA characterized 93% of European toxigenic C. difficile isolates resistant to fluoroquinolones, including the hypervirulent epidemic clone 027/NAP1/III (12, 34) . The remaining 7% showed a substitution in position 426 (Asp to Asn or Val) of GyrB (34) .
Few data on fluoroquinolone resistance of C. difficile clinical isolates are available for Italy (34) and, for this reason, we analyzed a convenient sample of toxigenic isolates, collected by the Istituto Superiore di Sanità (ISS) from 1985 to 2008, for substitutions in GyrA and GyrB and for their MIC values to moxifloxacin. All C. difficile resistant strains were also tested for their resistance to ciprofloxacin, gatifloxacin, and levofloxacin and investigated for a possible association between fluoroquinolone and MLSB resistance. Typing of resistant isolates was carried out using the already-described PCR ribotyping method (5).
MATERIALS AND METHODS

C. difficile clinical isolates.
A total of 147 toxigenic C. difficile isolates, selected from the ISS C. difficile national collection, were analyzed. These strains were isolated from sporadic cases and five different outbreaks between 1985 and 2008 and were sent to ISS by nine different Italian hospitals (arbitrarily denominated from A to I) located in the center and north of Italy for toxigenic assays and/or molecular analysis.
An outbreak was defined as two or more related cases over a locally defined period, whereas a sporadic case of CDI was defined as diarrhea (Ն3 loose stools per day for at least 2 days) in a patient with a stool culture positive for C. difficile and/or fecal cytotoxin B (18) .
C. difficile strains are voluntarily sent to ISS, so the number of strains received each year from the different hospitals is variable, and it is possible that each hospital is not always represented in the different years. At least 50% of strains received per year were selected and included in the study. Only two C. difficile strains per outbreak and only one strain per single patient were considered for the analysis, whereas strains from sporadic cases were randomly selected. Since the attention to CDI has increased during the last years in our country, there has been a rise in the number of C. difficile strains received by our institute. From 1985 to 1989, we only received C. difficile strains isolated from outbreaks, and the six strains selected for this study represent three different epidemics that occurred in three different hospitals (A, B, and C). From the beginning of the 1990s a higher number of strains, isolated from both outbreaks and sporadic cases, was sent to ISS by several hospitals. LightCycler gyr mutation assay. In the gyr mutation study, the presence of mutations conferring resistance in codon 82 of gyrA and codon 426 of gyrB was determined by using a LightCycler assay recently designed in our laboratory (35) . Briefly, purified genomic DNA, used as template, was isolated using the NucleoBond buffer set III and the NucleoBond AXG 20 (Macherey-Nagel, Düren, Germany). Amplification of targets was performed by an initial denaturation at 95°C for 10 min and 30 cycles of 95°C for 10 s, 49°C for 20 s, and 72°C for 20 s.
The melting curves for the annealing of the probes with the PCR product were determined from 42°C to 95°C, with a temperature transition rate of 0.1°C/s, by monitoring the reporter dye fluorescence emission at 640 nm (gyrB) or at 705 nm (gyrA). Data were analyzed with LightCycler software, version 5.32, according to the manufacturer's instructions. Different melting peaks characterized different nucleotide transitions.
The international reference strain, C. difficile 630, susceptible to fluorquinolones, was used as a representative of isolates showing gyr genes with a wild-type sequence.
Antibiotic susceptibilities. MICs to moxifloxacin (MX), levofloxacin (LE), gatifloxacin (GA), ciprofloxacin (CI), erythromycin (EM), and clindamycin (CM) were determined using the Etest (AB Biodisk, Solna, Sweden) on brucella agar plates containing vitamin K 1 (0.5 mg/liter), hemin (5 mg/liter), and 5% defibrinated sheep red blood cells, according to the manufacturer's instructions. The breakpoint used for all antibiotics tested in the study was 8 g/ml, in accordance with the guidelines established by the Clinical and Laboratory Standards Institute (CLSI) (8) . Bacteroides thetaiotaomicron ATCC 29741 was used as a control strain.
Detection of erm(B) genes. Since erm(B) is known to be predominant in MLSB-resistant C. difficile, the presence of genes belonging to this class was investigated by PCR using primers E5 and E6, as previously described (32) . Five microliters of crude DNA was denatured for 5 min at 94°C and amplified for 30 cycles consisting of 1 min at 94°C, 1 min at 50°C, and 1 min 30 s at 72°C. The expected size of the PCR fragment was 0.6 kb.
PCR ribotyping and phylogenetic analysis. PCR ribotyping analyses were performed by using the method of Bidet et al. (5) . The first isolate identified for each PCR ribotype was submitted to the Anaerobe Reference Laboratory, University Hospital of Wales, Cardiff, United Kingdom, to be assigned to a reference type of the United Kingdom collection.
The genomic DNA fingerprinting patterns produced by PCR ribotyping were compared and analyzed with GelCompar II v6.0 (Applied Maths, Sint-MartensLatem, Belgium). Similarity analysis was performed by using Pearson's correlation with a 0.5% optimization. Clustering was performed by using the unweighted pair group mean association (UPGMA). C. difficile strains showing a percentage of similarity of Ն90% were considered closely related.
RESULTS
Detection of mutations in gyr genes and resistance to fluoroquinolones. In total, 50 of the 147 (34%) isolates showed mutations in gyr genes. As far as the mutation in gyrA is concerned, we identified 48 strains with a T m of about 52.2°C (Fig.  1A ). This T m characterizes the transition of ACT (Thr) to ATT (Ile) in codon 82 of gyrA, whereas a melting peak at about 59.3°C characterized the wild-type gyrA sequence (35) . gyrB analysis showed that two strains had a T m at about 52.8°C, indicating the presence of the transition GAT (Asp) to AAT (Asn) in position 426 of the gene (Fig. 1B) (35) . All the other strains had a T m of about 58.3°C, which characterizes gyrB genes without mutations in position 426. The substitutions identified in this study have been previously described for C. difficile isolates (34) . In general, MIC values for MX ranged from 0.5 to Ն32 g/ml. Etest values for MX confirmed the results obtained by real-time PCR; in fact, all strains without substitutions in gyr genes were susceptible, whereas the 50 isolates showing substitutions were resistant to MX, with MICs between 8 and Ն32 g/ml. The MIC ranges of these strains for the other fluoroquinolones tested were as follows: 8 to Ն32 g/ml for GA, 24 to Ն32 g/ml for CI, and Ն32 g/ml for LE. Resistant strains with different mutations did not show significant differences in MIC levels for the fluoroquinolones tested in this study. In the group of strains isolated from 1985 to 2001 we found 10% (7/70) of C. difficile isolates were resistant to fluoroquinolones, whereas in the second group, from 2002 to 2008, the percentage rose to 56% (43/77).
Association with MLSB resistance and detection of erm(B) genes. Ninety-eight percent (49/50) of the C. difficile isolates resistant to fluoroquinolones were also resistant to EM and/or CM. MIC levels ranged between 1 and Ն256 g/ml for EM and between 0.5 and Ն256 g/ml for CM. In total, only eight C. difficile MLSB-resistant isolates (16%) showed an erm(B) gene. In particular, among the resistant strains isolated from 1985 to 2001 we found that 57% (4/6) had an erm(B) gene, whereas among those isolated from 2002 
and 2008 the erm(B)-positive isolates only represented 9% (4/43). All isolates with an erm(B)
gene were resistant to both EM and CM (MICs between 16 and 256 g/ml and 12 and 256 g/ml, respectively). C. difficile isolates that were erm(B) negative were resistant to EM (MICs, Ն256 g/ml) and resistant (MICs between 8 and 16 g/ml) or susceptible to CM, except for one isolate susceptible to EM and resistant to CM (MICs of 3 and 12 g/ml, respectively).
PCR ribotyping and phylogenetic analysis. Phylogenetic analysis indicated that C. difficile strains resistant to fluoroquinolones belong to two distinct clusters (Fig. 2) . The first one grouped PCR types 001 and 020 and the two control strains, typed as 027 and 017; the second cluster included PCR types 012, 018, 078, and 126. Interestingly, types 078 and 126 were closely related genetically, showing 91.3% similarity, whereas type 018 belonged to the more distant branch, showing only 57.9% similarity in comparison with the other types included in the same cluster.
DISCUSSION
Fluoroquinolones, in particular the broad-spectrum C-8-methoxyfluoroquinolones, are a class of antibiotics with a wide spectrum of activity that have been used extensively to treat a great variety of infections since the 1990s (13, 29) . Fluoroquinolone resistance has recently increased in C. difficile clinical isolates, so the use of fluoroquinolones has emerged as an important risk factor for CDI (2, 6, 7, 24, 26) . In Italy, the classes of drugs most affecting national expenditure for antibiotics are macrolides (23.8%) and quinolones/fluoroquinolones (21.3%) (31) Ninety-six percent of the C. difficile resistant isolates showed the substitution Thr82 to Ile in GyrA, as already observed in the majority of resistant C. difficile strains worldwide (34) . Only two isolates had the substitution Asp426 to Asn in GyrB, which was previously described in some C. difficile strains (34) . The results also confirmed the effectiveness of the LightCycler assay that we recently set up to detect mutations in codons 82 and 426 of gyrA and gyrB, respectively (35) . In fact, all strains showing substitutions resulted in resistance to fluoroquinolones, and no discrepancies were detected. For this reason, the LightCycler assay can be considered a cost-effective, fast, and reproducible alternative to screen several C. difficile strains for fluoroquinolone resistance in comparison with DNA sequencing and susceptibility testing, which are more time-consuming. The limits of this method are that mutations occur in different codons and the resistance due to other mechanisms, such as efflux, that occurs even if these mechanisms seems to be absent in C. difficile.
As for erythromycin and clindamycin resistance, 58% (29/ 50) of the strains examined were resistant only to erythromycin, 38% (19/50) to both erythromycin and clindamycin, and 2% (1/50) only to clindamycin. Interestingly, 84% (41/49) of the C. difficile isolates resistant to erythromycin and/or clindamycin were erm(B) negative. In a previous study (32) , we observed an increased number of erm(B)-negative clinical isolates in Italy from 1990 to 2001. The results obtained in the present study seem to confirm this trend. Since C. difficile erm(B)-negative strains are also negative for other important erm classes and efflux pumps (33) , further studies will be necessary to identify the mechanism of resistance present in these strains.
The use of MLSB antibiotics and fluoroquinolones has been known to be one of the major risk factors for CDI (15, 25, 6, 24, 26) . Overall, coresistance to moxifloxacin and erythromycin was found in 96% (48/50) of the C. difficile isolates analyzed in this study, confirming the high percentage of association also observed in other countries (1, 14) . The accumulation and maintenance of different mechanisms of resistance, such as transferable genetic elements and nucleotide mutations, make C. difficile resistant to an increased number of antibiotics, limiting therapeutic options and management of severe infections.
The majority of the fluoroquinolone-resistant strains analyzed in this study belonged to PCR ribotype 126 or 018. Both PCR ribotypes were responsible either for sporadic cases or outbreaks. PCR ribotype 126 was the most frequent from 2002 to 2005, whereas PCR ribotype 018 was predominant in 2007 and 2008. Both PCR ribotypes have already been identified among human isolates (2, 9, 23, 28) ; furthermore, these PCR ribotypes have also been isolated from animals (10, 17) . The two predominant types, A and R, found in our country between 1990 and 2001 (32) were assigned to PCR ribotypes 012 and 078, respectively, in this study. Phylogenetic analysis showed that isolates of PCR ribotypes 126 and 078 had a high percentage of similarity (92.3%). We found that 62% of the old Italian strains belonging to PCR ribotype 078 were resistant to erythromycin, erm(B) negative (32, 33) , and susceptible to fluoroquinolones. Since isolates of PCR ribotypes 078 and 126 are closely related genetically, it is possible that the progenitor of resistant strains, PCR ribotype 126, is derived from an erm(B)-negative C. difficile PCR ribotype 078 isolate that was subsequently selected, by fluoroquinolone pressure, for its resistance to these antibiotics.
As far as PCR ribotype 018 is concerned, phylogenetic analysis indicates that it is not related to the types previously found in our country, so it seems to be a "new" PCR ribotype for Italy. Interestingly, this PCR ribotype represents 51% of the total number of strains analyzed in our institute since 2006 (data not shown). All Italian isolates belonging to this PCR ribotype were found to be resistant to fluoroquinolones, suggesting that the increased use of these antibiotics has played a determinant role in selection and spread of these strains. PCR ribotype 018 has rarely been identified in other countries (9, 28, 37) and, unfortunately, no data are available on their susceptibility to fluoroquinolones. C. difficile strains of PCR ribotype 018 do not present the typical characteristics of the current hypervirulent strains; in fact, they are typed as toxinotype 0, are binary toxin negative (36) , and do not have significant changes in the regulatory toxins genes tcdD and tcdC, as demonstrated by our analysis on the pathogenicity locus (PaLoc) (data not shown). Besides resistance to fluoroquinolones, the capability to spread and cause disease for these strains may be due to other virulence factors, so a further characterization of isolates of PCR ribotype 018 is ongoing in our laboratory.
Overall, the results obtained in this study indicate an increasing number of C. difficile strains resistant to fluoroquinolones in our country and a change in the prevalence and type of the C. difficile isolates circulating over time. The results highlight the importance of typing of isolates and monitoring antimicrobial susceptibility for rapid detection of changes in C. difficile populations and rapid responses to the emergence of epidemic clones.
